


FCM PTO-1449 (REV. 1-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 52339AUSM1		APPLICATION NO. 10/642,255	
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Dole et al.			
				FILING DATE August 15, 2003		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
KKH	1.	WO 00/28076	18MAY00	PCT			
	2.	WO 00/62605	26OCT00	PCT			
	3.	Fleming, I. et al., "Phosphorylation of Thr ⁴⁹⁵ Regulates Ca ²⁺ /Calmodulin-Dependent Endothelial Nitric Oxide Synthase Activity," <i>Circ Res</i> , 88:e68 -e75; 2001.					
	4.	Govers, R. et al., "Cellular Regulation of Endothelial Nitric Oxide Synthase," <i>Am J Physiol Renal Physiol</i> 280:F193-F206; 2001.					
	5.	Marletta, M. A., "Another Activation Switch for Endothelial Nitric Oxide Synthase: Why does it have to be so complicated," <i>TRENDS in Biochemical Sciences</i> Vol.26:No.9; 2001.					
	6.	Mitchell, B. J. et al., "Coordinated Control of Endothelial Nitric-Oxide Synthase Phosphorylation by Protein Kinase C and the cAMP-dependent Protein Kinase," <i>J. Biol. Chem.</i> , 276: 17625 - 17628; 2001.					
	7.	Smith, R. S. et al., "Human Endothelial Nitric Oxide Synthase Gene Delivery Promotes Angiogenesis in a Rat Model of Hindlimb Ischemia," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22: 1279 - 1285; 2002.					
↓	8.	Rissanen, T. T. et al., "Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic," <i>Eur J Clin Invest</i> 31(8):651-666; 2001.					
EXAMINER Kevin K. Hill				DATE CONSIDERED January 4, 2007			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

Sheet 1 of 1

FORM PTO-1419 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 52339AUSM1	APPLICATION NO. US10/642,255
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS DOLE et al,	
		FILING DATE August 15, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO

KKH	1.	KAUSER et al, Bone marrow progenitor mediated postishhemic blood flow recovery and limb salvage in a mouse model of critical limb ischemia. <i>Experimental Hematology</i> 2003
	2.	MESSINA et al, Therapeutic angiogenesis for critical limb ischemia: invited commentary <i>Journal of Controlled Release</i> 2002. Vol. 78, pages 285-294, especially pages 285 and 287-293.
	3.	BROUET et al, Hsp90 ensure the transition from early Ca ²⁺ -dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor exposed endothelial cells <i>The Journal of Biological Chemistry</i> , August 2001, Vol. 276, No. 35. Pages 32663-32669
	4.	FULTON et al, Regulation of endothelium-derived nitric oxide production by the protein kinases Akt <i>Nature</i> June 1999, Vol. 399 pages 597-601
↓	5.	KHURANA et al, Gene therapy for cardiovascular disease <i>Hypertension</i> 2001, Vol. 38 pages 1210-1216
	6.	
	7.	

EXAMINER Kevin K. Hill	DATE CONSIDERED January 4, 2007
------------------------	---------------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Forms/Pat/P7-27 [01/31/01]